Study of ABI-6250 for chronic hepatitis D
This trial tests an experimental medicine called ABI-6250 for people with chronic hepatitis D. The goal is to see if it is safe and can help control the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis D (and hepatitis B).
- Your body mass index (BMI) is between 18 and 35.
- You are generally healthy apart from hepatitis B and D.
- You have not had hepatitis D treatment in the last 6 months.
- You are not currently infected with hepatitis A, C, or HIV.
- You must agree to use effective birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
This trial tests a new drug called Hepalatide for people with chronic hepatitis D (a liver infection). You must already have hepatitis B and be on a stable antiviral for it. The study checks if Hepalatide can safely lower HDV levels.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
Hear when a new Chronic Hepatitis D Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.